Browse EX-10 agreements

Document

Exhibit 10.1

Quanterix

900 Middlesex Turnpike | Building 1

Billerica, MA 01821

Jason Faessler

Delivered via Email

Re: Employment Agreement

Dear Jason:

Quanterix Corporation (the "Company") is pleased to offer you the full-time, exempt position of Chief Financial Officer, reporting to Everett Cunningham, Chief Executive Officer. Your start date will be June 22, 2026. This role is required to be in our Billerica, MA office.

Congratulations on this offer and career opportunity with Quanterix!

1. Base Salary: The Company will pay you a salary at an annual rate of $475,000.00, paid at a bi-weekly rate of $18,269.23 (less all applicable taxes and deductions), subject to periodic review and adjustment at the discretion of the Company.

…

June 8, 2026

 

Jared Oasheim 

joasheim@cvrx.com

 

Re:           Employment Transition Agreement

 

Dear Jared,

 

I want to thank you for your service to CVRx, Inc. (the “Company”). I understand you have chosen to transition from CVRx and appreciate your willingness to effect a smooth transition as outlined in this letter agreement (“Agreement”).

 

1.             Transition and Resignation from Employment. You hereby confirm your resignation as an officer of the Company and any of its subsidiaries and affiliates, effective as of the end of the day on the day preceding the Officer Transition Date (as outlined below), and your resignation as an employee of the Company as of the Separation Date (as outlined below). You agree to continue to serve as the Chief Financial Officer of the Company until the Officer Transition Date. The “Officer Transition Date” is the date on which your successor as Chief Financial Officer commences employment with the Company in such role, or such other date as the Company determines to initiate a transition of your officer role. Th

…

​

​

​

​

​

Exhibit 10.1

​

SECURITIES PURCHASE AGREEMENT

​

This Securities Purchase Agreement (this “Agreement”) is dated as of June 5, 2026, between Aspira Women’s Health, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature page hereto (including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

​

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

​

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

​

…

EXECUTION VERSION

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. REDACTED INFORMATION IS INDICATED BY [***]

 

 

 

LIMITED LIABILITY COMPANY AGREEMENT

 

OF

 

SOLUNA MB KK II JVCO, LLC

 

Dated as of June 3, 2026

 

 

 

THE LIMITED LIABILITY COMPANY INTERESTS REPRESENTED BY THIS LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS. SUCH INTERESTS MAY NOT BE SOLD, ASSIGNED, PLEDGED OR OTHERWISE DISPOSED OF AT ANY TIME WITHOUT EFFECTIVE REGISTRATION UNDER SUCH ACT AND LAWS OR EXEMPTION THEREFROM, AND COMPLIANCE WITH THE OTHER RESTRICTIONS ON TRANSFERABILITY SET FORTH HEREIN.

 

 

 

TABLE OF CONTENTS

 

 

 

Page

 

 

 

ARTICLE I

DEFINITIONS

2

 

 

 

ARTICLE II

ORGANIZATION

2

 

 

 

2.01.

Formation

2

2.02.

Name

2

2.03.

Registered Agent; Registered Office

…

Execution Version

TENDER AND SUPPORT AGREEMENT

This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of June [•], 2026, is entered into by and among GlaxoSmithKline LLC, a Delaware limited liability company (“Parent”), Harmony Row Acquisition Co., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”), and one or more stockholders of Nuvalent, Inc., a Delaware corporation (the “Company”), set forth on Schedule A hereto (each, a “Stockholder” and, if applicable, collectively, the “Stockholders”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

…

22nd Century Group, Inc.

321 Farmington Road

Mocksville, North Carolina 27028

(336) 940-3769

 

Dated as of June [  ], 2026

 

To Holders of Common Stock Purchase Warrants

 

Re: Inducement Offer to Exercise Common Stock Purchase Warrants

 

Dear Holder:

 

22nd Century Group, Inc. (the “Company”) is pleased pursuant to this letter agreement (this “Agreement”) to offer to you the opportunity to exercise all or part of the warrants of the Company beneficially owned by you: (i) on August 27, 2025 and (ii) on March 23, 2026 (collectively, the “Existing Warrants”) as set forth on the signature page hereto (the “Holder”), exercisable for the number shares of the Company’s common stock, par value $0.00001 per share, as set forth in such Existing Warrants (the “Existing Warrant Shares”). The Existing Warrant Shares were registered on a registration statement on Form S-3 (File Nos. 333-270473 and 333-294792). Capitalized terms not otherwise defined herein shall have the meanings set forth in the Existing Warrants.

…

Cocrystal Pharma, Inc.

 

James Sapirstein

4162 NW Briarcliff Circle

Boca Raton, Florida 33496

 

Dear James:

 

On behalf of Cocrystal Pharma, Inc. (the “Company”), we take great pleasure in confirming our employment offer, as Chief Executive Officer, with an anticipated start date of June 3, 2026. This position reports to the Board of Directors. We believe that you will be an excellent addition to the Company. Accordingly, the Company desires to retain you as an employee on the terms and conditions set forth in this letter.

 

Salary. You will be paid a biweekly rate of $10,192.31 (this amount is equivalent to $265,000 annually), subject to all regular applicable taxes, payable in accordance with the Company’s prevailing payroll practices. Your base salary will be reviewed periodically and at least at the conclusion of each Calendar year and may be increased based on your individual performance or increases in competitive market conditions pursuant to the Company’s executive compensation policies.

 

Stock Option Inducement Grant.

…